Ligand Doubles Royalty Portfolio with $739M XOMA Acquisition — Ligand Pharmaceuticals Incorporated

Event summary

Ligand completed its $739M acquisition of XOMA Royalty on July 14, 2026.
The deal adds seven commercial products and over 100 development-stage assets to Ligand's portfolio.
Ligand's total royalty assets now exceed 200, more than doubling its previous size.
Transaction is expected to be immediately accretive, adding $0.50-$1.50 per share to adjusted EPS in 2026-2027.

The big picture

This acquisition positions Ligand as one of the largest biopharmaceutical royalty aggregators, with a portfolio spanning over 200 assets. The deal reflects an industry trend toward consolidation among royalty aggregators seeking to diversify revenue streams and reduce risk through broad exposure to commercial and developmental-stage products. The strategic move comes as biotech financing becomes increasingly competitive, with companies looking for non-dilutive funding options.

What we're watching

Integration Challenges: Whether Ligand can successfully integrate XOMA's diverse portfolio without operational disruption.
Earnings Impact: The pace at which the acquisition contributes to Ligand's adjusted EPS and long-term growth.
Portfolio Performance: How the newly added assets, particularly those in late-stage development, perform commercially.